ERBB4 and neoplasm: In vitro and in vivo studies exposed that LINC00152 promotes tumor progression and epithelial-to-mesenchymal transition process in colon cancer and glioblastoma tumors, respectively, trough modulating the LINC00152/miR-193a-3p/ERBB4/AKT signaling pathway and inhibiting miR-107 and miR-16 expression [31,34,35].